NCT06778863 - A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

June 30, 2028

Conditions

Advanced Solid TumorUnresectable Solid TumorMetastatic Solid TumorColorectal AdenocarcinomaPancreatic AdenocarcinomaLung CancerOvarian CancerBreast CancerHead and Neck Squamous Cell CarcinomaProstate CancerBladder Cancer

Interventions

DRUG

CLSP-1025

CLSP-1025 will be administered by IV infusion

Trial Locations (15)

10016

RECRUITING

NYU Langone Health, New York

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

19107

RECRUITING

Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia

19111

RECRUITING

Fox Chase Cancer Center, Philadelphia

33136

RECRUITING

University of Miami - Sylvester Comprehensive Cancer Center, Miami

37203

RECRUITING

Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville

40536

RECRUITING

University of Kentucky Markey Cancer Center, Lexington

75246

RECRUITING

Baylor University Medical Center, Dallas

77030

RECRUITING

MD Anderson Cancer Center, Houston

85258

RECRUITING

HonorHealth Research Institute, Scottsdale

85719

RECRUITING

The University of Arizona Cancer Center, Tucson

90033

RECRUITING

USC - Norris Comprehensive Cancer Center, Los Angeles

94143

RECRUITING

University of California San Francisco, San Francisco

95817

RECRUITING

University of California Davis Comprehensive Cancer Center, Sacramento

07601

RECRUITING

Hackensack University Medical Center, Hackensack